Glecaprevir Pibrentasvir LA injection

Drug information

Delivery device(s)

No delivery device

Scale-up prospects

Not provided

Tentative equipment list for manufacturing

Not provided

Manufacturing

Not provided

Specific analytical instrument required for characterization of formulation

Not provided

Proprietary excipients used

No proprietary excipient used

Novel excipients or existing excipients at a concentration above Inactive Ingredients Database (IID) for the specified route of administration

No novel excipient or existing excipient used

Residual solvents used

No residual solvent used

Description

long acting injectable liquid formulations comprising an aqueous dispersion of microparticles of glecaprevir and/or pibrentasvir stabilised by a first excipient and a second excipient.

Brief description

The present invention relates to long acting injectable liquid formulations comprising an aqueous dispersion of microparticles of glecaprevir and/or pibrentasvir stabilised by a first excipient and a second excipient. The present invention also relates to solid compositions which may be used as a precursor for the long acting injectable formulations, aqueous dispersions, microneedle arrays, implantable rods, and pharmaceutical compositions, methods of producing such long acting injectable formulations, and medical uses for such formulations and methods of treatment using such formulations.

Representative patent

WO2023052776

Category

Formulation

Patent holder

University of Liverpool

Exclusivity

Not provided

Expiration date

September 29, 2042

Status

Pending in EP, IN, US and CN

Publications

There are no publication

Additional documents

No documents were uploaded

Useful links

• A single-injection cure for hepatitis C virus in low- and middle-income countries

	Collaborate for development Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology Not provided
	Share technical information for match-making assessment Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit Not provided
	Work with MPP to expand access in LMICs In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing Not provided

Not provided